ESLA Dividend: Estrella Immunopharma Inc Yield Insights

Income

Balance sheet

Cash flow

Annual

Quarterly

ESLA Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	06/30/2024	06/30/2023	12/31/2022	06/30/2022
Revenue	0	0	0	0	0	0
Revenue Growth (YoY)	--	--	--	--	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	3	1	3	0	0	0
Research & Development	8	2	4	10	--	1
Operating Expenses	12	4	7	11	1	1
Other Non Operating Income (Expenses)	--	--	--	--	--	--
Pretax Income	-12	-4	-7	-11	0	-1
Income Tax Expense	0	0	0	0	0	0
Net Income	-12	-4	-7	-11	-1	-1
Net Income Growth	71%	-43%	-36%	1,000%	--	0%
Shares Outstanding (Diluted)	36.16	36.51	36.28	35.2	2.33	35.2
Shares Change (YoY)	-6%	1%	3%	1,411%	--	1,411%
EPS (Diluted)	-0.33	-0.12	-0.2	-0.31	-0.43	-0.04
EPS Growth	85%	-40%	-36%	-27%	--	-89%
Free Cash Flow	-3	-3	-16	-1	-1	-1
Free Cash Flow Per Share	-0.08	-0.08	-0.44	-0.02	-0.42	-0.02
Gross Margin	--	--	--	--	--	--
Operating Margin	0%	0%	0%	0%	0%	0%
Profit Margin	0%	0%	0%	0%	0%	0%
Free Cash Flow Margin	0%	0%	0%	0%	0%	0%
EBITDA	--	--	--	--	--	--
EBITDA Margin	--	--	--	--	--	--
D&A For EBITDA	--	--	--	--	--	--
EBIT	-12	-4	-7	-11	-1	-1
EBIT Margin	0%	0%	0%	0%	0%	0%
Effective Tax Rate	0%	0%	0%	0%	0%	0%